Table 1.
Consistency of clinical and radiological outcomes between oral therapies compared to current licensed therapies for RRMS; not from comparative studies
| Trial (length years) | Relapses
|
Progression
|
||
|---|---|---|---|---|
| Clinical: ARR | MRI: T2/Gd-enhancing lesions | Clinical: 12 week progression | MRI: T1 black holes | |
| BG-12 DEFINE (2) | Y, ✓ | Y, ✓ | Y | Y |
| BG-12 CONFIRM (2) | Y, ✓ | Y, ✓ | N, # | Y, # |
| Fingolimod FREEDOMS (2) | Y, ✓ | Y, ✓ | Y, ✓ | Y, ✓ |
| Fingolimod TRANSFORMS (1) | Y, ✓ | Y, ✓ | N, ✕ | N, ✕ |
| IFNβ (3) | Y, ✓ | Y, ✓ | N, ✕ | N, ✕ |
| GA (2) | Y, # | N, # | N, ✕ | N, ✕ |
| Natalizumab (2) | Y, ✓ | Y, ✓ | Y, # | N, # |
Notes: Y, positive effect; N, no effect; ✓, positive effect and consistent; #, inconsistent results between outcomes; ✕, no effect in both outcomes.
Abbreviations: ARR, annualized relapse rate; MRI, magnetic resonance imaging; GA, glatiramer acetate; Gd, gadolinium; IFN, interferon; RRMS, relapsing remitting multiple sclerosis.